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Glucocorticoid remediable aldosteronism (GRA) is a rare autosomal dominant' cause of primary aldosteronism originally described in 1966 by Sutherland et al' in a father and son with hypertension, low plasma potassium concentration, increased aldosterone secretion, increased plasma volume, and suppressed plasma renin activity, all of which were found to be reversed by low dose dexamethasone therapy. Further cases have been described of severe hypertension usually presenting at a young age with signs of primary aldosteronism correctable by glucocorticoids and in association with familial occurrence of hypertension6 and of cerebral haemorrhage.56 More recently the association of GRA with high levels of the abnormal hybrid steroids 1 8-hydroxycortisol7 and 18-oxocortisol8 has been reported.
We describe two pedigrees in which a total of 29 patients have been identified as possessing the abnormal 6-3 kb genomic DNA fragment, following restriction analysis and detected by Southern blotting, which is tightly linked to GRA. 9 In normal subjects, when genomic DNA is digested with the restriction enzyme BamHI, Southern blotted, and probed with a 11 3-hydroxylase specific probe, there are two bands on the resultant autoradiograph of 8-5 and 4 i5 kb, corresponding to 11 J-hydroxylase and aldosterone synthase respectively. 3 3, 3-1, and 3 8 mmol/1 (NR 3 5-4 9 mmol/l). A strong maternal family history ofhypertension was also noted with his mother (IV-17), grandmother (III8), and two uncles (IV-12 and IV-18) being hypertensive and, in addition, on examination one of his sisters (V-22), aged 23, was also found to be hypertensive. There was also a history ofcerebral haemorrhage in his maternal grandmother.
The proband had poor control of his blood pressure for many years while taking multiple antihypertensive medications and required several admissions to hospital. He had previously r-)S.
-;!,q --E .2)S. 4-1 mmol/l while taking dexamethasone 0-25 mg twice daily, amiloride 10 mg daily, bumetanide 1 mg daily, and quinapril 5 mg daily).
Additional family members were traced from the family history and records of marriages, births, and deaths for individual parishes ofnorth east Scotland. fig 6) , a 25 year old man, had severe hypertension diagnosed at the age of 15 following a school medical. After admission for blood pressure assessment he was found to have a resting blood pressure of 150/ 114 mmHg, serum urea 4 0 mmol/l, and potassium 3 9 mmol/l, and borderline criteria for left ventricular hypertrophy on ECG. There was a strong maternal family history of hypertension in his mother (IV.2), grandmother (III4), and uncle (IV-3). Despite antihypertensive medication there were problems with control. In 1993 he was noted to have hypokalaemic alkalosis with serum potassium 3-3 mmol/l and bicarbonate 34 mmol/l (NR 22-30 mmol/l). On further investigation, he was found to have raised plasma aldosterone levels (970, 1350 pmol/l (NR 100-400 pmol/l)) which was also suppressed to 220 pmol/I following two days of dexamethasone therapy at the dosage 0 5 mg twice daily. His The variation in phenotype of those having the mutation is illustrated by the immediate family members of the proband of family B. His mother (IV-2) was diagnosed as having borderline blood pressures from the age of 19 but was first treated for hypertension aged 28 (BP 150/115 mmHg) and has had normal serum biochemistry. She has been previously treated with a thiazide diuretic and is currently treated with amiloride 5 mg daily with good blood pressure control. The proband has two sisters both possessing the chimaeric gene of GRA on DNA analysis, neither of whom had a past medical history of hypertension. The oldest (V 5) is normotensive and has serum potassium within normal limits; the younger sister (VA4) had a borderline resting blood pressure but satisfactory daytime mean 24 hour ambulatory blood pressure (136/80 mmHg) and has not required therapy. At the time of diagnosis she had a potassium at the lower limit of normal (3 5 mmol/l 
